Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Phenex Pharmaceuticals and Janssen Biotech have collaborated to jointly develop compounds used in the treatment of chronic autoimmune and inflammatory disorders such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
Subscribe to our email newsletter
The research deal will focus on the identification of the compounds targeting nuclear hormone receptor ROR?T and optimized for preclinical development.
Advancement of the compounds resulting from the collaboration and commercialization activities will be carried out by Janssen.
Phenex CEO Dr. Claus Kremoser said the collaboration combines Phenex’s nuclear receptor knowledge, Janssen’s immunology expertise to discover new ROR?T based treatments for autoimmune diseases.
"We hope that small molecule drugs that target ROR?T will prove to be a safe, effective and affordable means to treat autoimmune disease, a marketplace within which there remains a need for differentiated therapies," Kremoser added.
According to the deal, Phenex will earn an upfront payment and is eligible for development and regulatory event based milestones in addition to sales-based tiered royalties and milestones.
Phenex CFO Thomas Hoffmann said, "The upfront payment and near-term milestones that may be achieved through this collaboration are quite important for Phenex as the funds received will make it possible for us to both collaborate with Janssen on ROR?T and continue the clinical development of our proprietary FXR program through the next few years."